{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T09:39:06Z","timestamp":1772357946067,"version":"3.50.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":730,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.jcf.2024.02.007","type":"journal-article","created":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T22:57:35Z","timestamp":1709333855000},"page":"203-207","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Year in review 2023 \u2013 Back to the future"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7677-6775","authenticated-orcid":false,"given":"Luca","family":"Cristiani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8969-4699","authenticated-orcid":false,"given":"Fl\u00e1via Fonseca","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jcf.2024.02.007_bib0001","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.jcf.2023.03.002","article-title":"Real-world safety and effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: interim results of a long-term registry-based study","volume":"22","author":"Bower","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.02.007_bib0002","doi-asserted-by":"crossref","unstructured":"Sutharsan S., Dillenhoefer S., Welsner M., Stehling F., Brinkmann F., Burkhart M., et al. Impact of elexacaftor\/tezacaftor\/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF Registry. Lancet Reg Health Eur. 2023;32:100690.","DOI":"10.1016\/S1569-1993(23)01220-1"},{"issue":"6","key":"10.1016\/j.jcf.2024.02.007_bib0003","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02029-2022","article-title":"Long-term safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension study","volume":"62","author":"Daines","year":"2023","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.jcf.2024.02.007_bib0004","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1164\/rccm.202301-0021OC","article-title":"Long-term safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor in children aged \u2a7e6 years with cystic fibrosis and at least one F508del allele: a phase 3, open-label clinical trial","volume":"208","author":"Wainwright","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.jcf.2024.02.007_bib0005","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1164\/rccm.202301-0084OC","article-title":"Phase 3 open-label clinical trial of elexacaftor\/tezacaftor\/ivacaftor in children aged 2-5 years with cystic fibrosis and at least one F508del allele","volume":"208","author":"Goralski","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.jcf.2024.02.007_bib0006","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1164\/rccm.202308-1317OC","article-title":"Improvement in lung clearance index and chest computed tomography scores with elexacaftor\/tezacaftor\/ivacaftor treatment in people with cystic fibrosis aged 12 years and older - the recover trial","volume":"208","author":"McNally","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.jcf.2024.02.007_bib0007","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.jcf.2023.08.002","article-title":"The impact of elexacaftor\/tezacaftor\/ivacaftor on fat-soluble vitamin levels in people with cystic fibrosis","volume":"22","author":"Hergenroeder","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.jcf.2024.02.007_bib0008","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jcf.2023.02.004","article-title":"Elexacaftor\/tezacaftor\/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del","volume":"22","author":"Lopez","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.02.007_bib0009","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02437-2022","article-title":"The French Compassionate Program of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del CFTR variant","author":"Burgel","year":"2023","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.jcf.2024.02.007_bib0010","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.jcf.2023.06.001","article-title":"Clinical and functional efficacy of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis carrying the N1303K mutation","volume":"22","author":"Sadras","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2024.02.007_bib0011","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1164\/rccm.202303-0380LE","article-title":"Raised intracranial pressure in three children with cystic fibrosis receiving elexacaftor-tezacaftor-ivacaftor modulator therapy","volume":"208","author":"Southern","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2024.02.007_bib0012","article-title":"Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor: multidimensional assessment of neuropsychological side effects and physical and mental health outcomes in adolescents and adults","author":"Graziano","year":"2023","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2024.02.007_bib0013","article-title":"Elexacaftor\/tezacaftor\/ivacaftor treatment and depression-related events","author":"Ramsey","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.jcf.2024.02.007_bib0014","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.jcf.2023.03.014","article-title":"A multidisciplinary model for prenatal care for patients with cystic fibrosis in the era of highly effective modulator therapy","volume":"22","author":"Li","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2024.02.007_bib0015","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.jcf.2023.09.008","article-title":"Standards for the care of people with cystic fibrosis (CF): a timely and accurate diagnosis","volume":"22","author":"Castellani","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.02.007_bib0016","article-title":"Standards for the care of people with cystic fibrosis; establishing and maintaining health","author":"Southern","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.jcf.2024.02.007_bib0017","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.jcf.2023.05.010","article-title":"Nutritional considerations for a new era: a CF foundation position paper","volume":"22","author":"Leonard","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2024.02.007_bib0018","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jcf.2023.02.011","article-title":"Position paper: models of post-transplant care for individuals with cystic fibrosis","volume":"22","author":"McKone","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2024.02.007_bib0019","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jcf.2022.08.010","article-title":"Prevalence, trends and outcomes of long-term inhaled antibiotic treatment in people with cystic fibrosis without chronic Pseudomonas aeruginosa infection - a European cystic fibrosis patient registry data analysis","volume":"22","author":"Orenti","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2024.02.007_bib0020","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jcf.2022.08.007","article-title":"Impact of antibiotic eradication therapy of Pseudomonas aeruginosa on long term lung function in cystic fibrosis","volume":"22","author":"Casaredi","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.jcf.2024.02.007_bib0021","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.chest.2023.05.024","article-title":"Effect of hypertonic saline on lung function as add-on treatment in people with cystic fibrosis receiving dornase alfa: a cystic fibrosis foundation patient registry analysis","volume":"164","author":"Kaditis","year":"2023","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2024.02.007_bib0022","series-title":"Prevalence and clinical impact of respiratory viral infections from the STOP2 study of cystic fibrosis pulmonary exacerbations","author":"Thornton","year":"2023"},{"key":"10.1016\/j.jcf.2024.02.007_bib0023","series-title":"Adjunctive systemic corticosteroids for pulmonary exacerbations of cystic fibrosis","author":"McElvaney","year":"2023"},{"issue":"8","key":"10.1016\/j.jcf.2024.02.007_bib0024","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/thorax-2023-220100","article-title":"A refresh of the top 10 research priorities in cystic fibrosis","volume":"78","author":"Rowbotham","year":"2023","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/j.jcf.2024.02.007_bib0025","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jcf.2023.04.007","article-title":"Willingness of people with cystic fibrosis receiving elexacaftor\/tezacaftor\/ivacaftor (ETI) to participate in randomized modulator and inhaled antimicrobial clinical trials","volume":"22","author":"VanDevanter","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2024.02.007_bib0026","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S2213-2600(22)00504-5","article-title":"Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials","volume":"11","author":"Uluer","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"4","key":"10.1016\/j.jcf.2024.02.007_bib0027","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.jcf.2023.04.008","article-title":"Inhaled mRNA therapy for treatment of cystic fibrosis: interim results of a randomized, double-blind, placebo-controlled phase 1\/2 clinical study","volume":"22","author":"Rowe","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2024.02.007_bib0028","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.jcf.2023.03.004","article-title":"FDA-approved drug screening in patient-derived organoids demonstrates potential of drug repurposing for rare cystic fibrosis genotypes","volume":"22","author":"de Poel","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.jcf.2024.02.007_bib0029","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jcf.2023.04.009","article-title":"Mobile health platform for self-management of pediatric cystic fibrosis: impact on patient-centered care outcomes","volume":"22","author":"Oates","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"10","key":"10.1016\/j.jcf.2024.02.007_bib0030","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1002\/ppul.26602","article-title":"Unsupervised home spirometry is not equivalent to supervised clinic spirometry in children and young people with cystic fibrosis: results from the CLIMB-CF study","volume":"58","author":"Edmondson","year":"2023","journal-title":"Pediatr Pulmonol"},{"issue":"9","key":"10.1016\/j.jcf.2024.02.007_bib0031","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1164\/rccm.202305-0844LE","article-title":"Cell-Free DNA detects pseudomonas aeruginosa lung infection in modulator-treated people with cystic fibrosis","volume":"208","author":"Long","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.jcf.2024.02.007_bib0032","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jcf.2023.02.010","article-title":"Exhaled breath profiles to detect lung infection with Staphylococcus aureus in children with cystic fibrosis","volume":"22","author":"Licht","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.jcf.2024.02.007_bib0033","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00174-2023","article-title":"Prevalence, risk factors and outcomes of cardiac disease in cystic fibrosis: a multinational retrospective cohort study","volume":"62","author":"Frost","year":"2023","journal-title":"Eur Respir J"},{"issue":"10","key":"10.1016\/j.jcf.2024.02.007_bib0034","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1164\/rccm.202209-1653OC","article-title":"Genetic modifiers of cystic fibrosis lung disease severity: whole-genome analysis of 7,840 patients","volume":"207","author":"Zhou","year":"2023","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324000225?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324000225?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T08:24:30Z","timestamp":1772353470000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199324000225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S1569199324000225"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2024.02.007","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Year in review 2023 \u2013 Back to the future","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2024.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}